Consumer Impact Statement - intermittent claudication
CHF was contracted by the Department of Health and Ageing to develop a Consumer Impact Statement for the Pharmaceutical Benefits Advisory Committee (PBAC) on intermittent claudication.
Intermittent claudication is pain or cramping in the lower leg due to inadequate blood flow to the muscles, caused by poor oxygen supply due to a temporary narrowing of the arteries that supply the leg with blood. It is most commonly associated with peripheral arterial disease, and is more common in people with high cholesterol, high blood pressure and diabetes, and people who smoke or are overweight.
CHF sought consumer input on the impact of intermittent claudication on the activities of daily living and mobility, including, but not limited to:
- How intermittent claudication manifests itself
- How intermittent claudication impacts on general well being
- How intermittent claudication impacts on activities of daily living
- How intermittent claudication impacts family members and carers.
The Consumer Impact Statement was provided to the Department in June 2010.